VAXNEUVANCE

Merck Sharp & Dohme LLC🇺🇸 United States

FDA Page

Effective Date: Jun 17, 2026
Approval ID: 1158fa93-ef41-4a29-8252-9251f94c53c8
Products: 1 registered
Version: 15

Regulatory Information

Labeling Type

VACCINE LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use VAXNEUVANCE safely and effectively. See full prescribing information for VAXNEUVANCE. VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine)injectable suspension, for intramuscular useInitial U.S. Approval: 2021

Quick Stats

Total Products1

Labelers1

Label Sections16

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.